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PTPN22 encodes the lymphoid tyrosine phosphatase (LYP) and
is the second strongest non-HLA genetic risk factor for type 1
diabetes. The PTPN22 susceptibility allele generates an LYP var-
iant with an arginine-to-tryptophan substitution at position 620
(R620W) that has been reported by several studies to impart
a gain of function. However, a recent report investigating both
human cells and a knockin mouse model containing the R620W
homolog suggested that this variation causes faster protein deg-
radation. Whether LYP R620W is a gain- or loss-of-function vari-
ant, therefore, remains controversial. To address this issue, we
generated transgenic NOD mice (nonobese diabetic) in which
Ptpn22 can be inducibly silenced by RNA interference. We found
that Ptpn22 silencing in the NOD model replicated many of the
phenotypes observed in C57BL/6 Ptpn22 knockout mice, includ-
ing an increase in regulatory T cells. Notably, loss of Ptpn22 led
to phenotypic changes in B cells opposite to those reported for
the human susceptibility allele. Furthermore, Ptpn22 knockdown
did not increase the risk of autoimmune diabetes but, rather,
conferred protection from disease. Overall, to our knowledge,
this is the ﬁrst functional study of Ptpn22 within a model of type
1 diabetes, and the data do not support a loss of function for the
PTPN22 disease variant. Diabetes 62:896–904, 2013
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TPN22 encodes the lymphoid tyrosine phos-
phatase (LYP) (1) that has been shown to
modulate the activation of both T and B cells
(2,3). PTPN22 variation is associated with au-
toimmunity (4–6) and is the second most signiﬁcant ge-
netic risk factor for type 1 diabetes outside the HLA region
(4,7). The PTPN22 1858T allele confers susceptibility to
autoimmune diabetes because of an arginine to tryptophan
substitution at position 620 (R620W) in the LYP protein.
The R620W variation disrupts the association of LYP with
Csk, a negative regulatory kinase (4), and a model was
proposed in which this disruption causes increased phos-
phatase activity of LYP (8,9). It was suggested that R620W
is a gain-of-function variant that dampens activation of T
and B cells in response to antigen receptor ligation
(3,8,10,11). Diminished signaling was indeed observed in
both T and B cells from individuals carrying the 1858T
allele (3,8,11). Several hypotheses have proposed how
hyporeactivity may affect both T-cell (8) and B-cell (11,12)
tolerance. Impaired T-cell receptor signaling could facilitate
the escape of autoreactive T cells during thymic selection,
impair the selection or activation of regulatory T (Treg)
cells, or prevent the peripheral tolerization of autoreactive
clones (8). Similarly, B cells may escape tolerance mech-
anisms by virtue of diminished activation and resistance to
apoptosis in response to antigenic stimuli in individuals
carrying the 1858T allele (11,12). Although these hypoth-
eses provide a plausible explanation for the association of
PTPN22 variation with autoimmunity, a recent publication
reported data incompatible with this model (13). Using
human samples and knockin mice carrying the homolog of
the human LYP R620W variant (PEST domain-enriched
tyrosine phosphatase [PEP] 619W in mouse), this study
suggested that the disease variant protein was prone to
rapid degradation, making PTPN22 1858T a loss-of-function
allele. Results from these contradictory studies are difﬁcult
to reconcile. Therefore, whether LYP R620W is a gain- or
loss-of-function variant remains controversial.
Characterization of Ptpn22-deﬁcient C57BL/6 (B6) mice
has provided more detailed insights into the role of this
gene in lymphocyte function. In mice, Ptpn22 encodes the
LYP homolog PEP. Loss of PEP was shown to facilitate
positive selection but to have no impact on negative se-
lection (14). The most notable effect observed in Ptpn22
knockout (KO) mice was the accumulation of effector/
memory T cells (Teff) and their hyperreactivity compared
with wild-type (WT) cells. In addition, Ptpn22 deﬁciency
led to splenomegaly and lymphadenopathy in older mice
but without causing autoimmune pathogenesis. A sub-
sequent study showed that these mice also accumulated
increased numbers of Treg cells (15), providing a possible
explanation for the lack of overt autoimmunity in Ptpn22-
deﬁcient animals. Moreover, this same study demonstrated
that Ptpn22 KO mice are less susceptible to the experi-
mental autoimmune encephalomyelitis (EAE) model of
multiple sclerosis (15). Although the original description of
Ptpn22 KO mice suggested that the loss of this gene may
predispose to autoimmunity, the latter report implies,
rather, that loss of Ptpn22 may have an overall protective
effect against autoimmune disease.
Because the LYP susceptibility variant R620W was
reported to be gain of function (3,8–11), LYP inhibition
was proposed as a potential therapeutic approach for type
1 diabetes (8,16). To investigate the function of PTPN22 in
autoimmune diabetes and to evaluate whether inhibition of
this gene may protect from disease, we generated trans-
genic NOD mice (nonobese diabetic) in which Ptpn22
can be silenced by RNA interference in a doxycycline-
dependent manner. Gene silencing recapitulated pheno-
typic changes observed in Ptpn22 KO B6 mice. Ptpn22
knockdown (KD) did not, however, increase the risk of
autoimmune diabetes in the NOD model, as would be
predicted from the recent report claiming that LYP R620W
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ORIGINAL ARTICLEis a loss-of-function variant. Instead, the ﬁndings support
the notion that the susceptibility allele of PTPN22 is a gain-of-
function variant.
RESEARCH DESIGN AND METHODS
Mice. All mice were bred and maintained under speciﬁc pathogen-free con-
ditions at the University ofWürzburgin accordancewith institutional guidelines.
Lentiviral transgenic P2 and P4 mice were generated as described previously
(17). Brieﬂy, lentivirus carrying an inducible short hairpin RNA (shRNA) ex-
pression cassette that targets the sequence GATGAGGATTCCAGTTATA (P2)
or GCATCTGTACACATCTTTA (P4) in the Ptpn22 mRNA was microinjected
into NOD zygotes. For induction of gene silencing, mice were treated with 200
mg/mL doxycycline in the drinking water, unless otherwise noted. All experi-
ments were approved by the Regional Government of Lower Franconia in ac-
cordance with German animal protection laws.
Lentiviral construct for inducible shRNA expression. The inducible
shRNA expression system consists of two vectors, pH1tet-ﬂex and FH1t-UTG
(provided by Marco J. Herold) (18). The vector pH1tet-ﬂex was digested with
the restriction enzymes BbsI and XhoI. The backbone was recovered and
annealed with P2 or P4 shRNA. The fragment containing the H1 promoter and
tet-operator was digested with PacI and inserted into the ﬁnal vector
FH1t-UTG. Positive clones were screened by colony PCR and veriﬁed by
sequencing.
Luciferase reporter assay. Ptpn22 cDNA was cloned into the psiCheck2
vector (Promega). 293-F cells were cotransfected with 100 ng psiCheck2
Ptpn22 reporter construct and 300 ng shRNA-containing vector in the
presence or absence of 3 mg/mL doxycycline. Fireﬂya n dRenilla luciferase
activity was measured in cell lysates using a Fluostar Optima luminometer
48 h later.
Quantitative RT-PCR and Western blot. Total RNA was extracted from
lymphocytes and reverse-transcribed with a ﬁrst-strand cDNA synthesis kit
(Roche). Ptpn22 mRNA was quantiﬁed with the following primers and Universal
Probe Library (UPL) probes (Roche): 1) GAPDH,f w d5 9-agcttgtcatcaacgggaag-39,
rev 59-tttgatgttagtggggtctcg-39,U P Lp r o b e9 ,a n d2) PTPN22, fwd
59-cagaacgtgttcagccaaaa-39, rev 59-ttggtcctttgcgttttgaa-39, UPL probe 17. For
the Western blot, lymphocytes were lysed in radioimmunoprecipitation assay
buffer supplemented with 10% protease inhibitor cocktail (Sigma-Aldrich) on
ice for 30 min. The protein concentration was measured with a bicinchoninic
acid protein assay kit (Novagen). Target proteins were probed with the anti-
bodies against PEP (1:1,000) (gift from Andrew C. Chan), actin (1:2,000)
(Sigma-Aldrich), and tetracycline repressor (TetR) (1:1,000) (Mobitec).
Flow cytometry. All ﬂow cytometry measurements were performed on
a FACSCanto II ﬂow cytometer (BD Biosciences). A FoxP3 staining kit
(eBioscience) was used to identify FoxP3
+ Treg cells. Data were analyzed
using FlowJo software (Tree Star Inc.).
Treg-cell suppression assay. CD4
+CD25
2 Teff cells and CD4
+CD25
+ Treg
cells were puriﬁed by magnetic separation using a CD4
+CD25
+ isolation kit
(Miltenyi Biotech) according to the manufacturer’s instructions. CD4-depleted
WT splenocytes were irradiated (20 Gy) and used as antigen-presenting cells
(2.5 3 10
5/well). WT CD4
+CD25
2 Teff cells (2.5 3 10
4/well) were cocultured
with WT or Ptpn22 KD CD4
+CD25
+ Treg cells at the indicated ratios and
stimulated with 1 mg/mL anti-CD3 antibody in RPMI-1640 medium supplemented
with 10% FBS, penicillin/streptomycin, L-glutamine, 2-mercaptoethanol, sodium
pyruvate, and HEPES (all from Gibco/Invitrogen).
Treg induction. Naïve CD4
+CD62L
hi T cells were isolated using a MACS bead
kit (Miltenyi Biotech) according to the manufacturer’s instructions. Cells were
stimulated with 2 mg/mL anti-CD3, 2 mg/mL anti-CD28, and 0.5 ng/mL trans-
forming growth factor-b with or without 1 mg/mL doxycycline. The frequency
of FoxP3
+ cells was analyzed 72 h later.
Cell transfers. Cells were obtained from WT, P2, and P4 mice (2–4m i c ep e r
donor group) pretreated with doxycycline for 1 month. WT cells were mixed with
P2 or P4 cells at a 1:1 ratio and transferred into NOD.scid mice (severe combined
immunodeﬁciency) (3–4 per group) treated with doxycycline for the duration of
the experiment. Cell recipients were dissected 1 month after cell transfer to
measure CD44
hiCD62L
lo T-cell frequencies in lymph nodes and spleen.
Anti-CD3 stimulation in vivo. Ten micrograms anti-CD3 was injected in-
travenously into WT and transgenic mice pretreated with doxycycline for 10
days. Mice underwent dissection 2 days later for ﬂow cytometry analysis of
lymph node cells and splenocytes.
B-cell activation, proliferation, and apoptosis. B cells were puriﬁed from
splenocytes from mice pretreated with doxycycline for 1 month by positive or
negative selection with anti-CD19 or anti-CD43 microbeads (Miltenyi Biotech),
respectively. B cells were stimulated with LPS or the indicated concentration
of anti-IgM F(ab9)2 or anti-CD40 and stained with anti-CD69, anti-CD25, and
7-aminoactinomycin D (BD Biosciences) 24 h later to measure B-cell activation
and apoptosis. For proliferation assays, cells were pulsed with
3H-thymidine (0.5
mCi/well) after 48 h, and thymidine incorporation was measured 16 h later.
Measurement of phospholipase Cg2 phosphorylation after B-cell
activation. B cells were puriﬁed from mice pretreated with doxycycline for 1
month. WT and transgenic cells were mixed at a 1:1 ratio to control for interwell
variations.Bcellswerestainedwithanti-CD19monoclonalantibodyandrestedin
RPMI-1640 medium at 37°C for 10 min. Aliquots of 0.5 3 10
6 mixed B cells were
transferredtoa96-wellplateandactivatedwith40mg/mLanti-IgMF(ab9)2for1,3,
5, and 10 min. Cells were immediately ﬁxed with 150 mL Fix Buffer I (BD Bio-
sciences)at37°Cfor10min,thenwashed,andpermeabilizedwithPermBufferIII
(BD Biosciences) on ice for 15 min. Cells were stained with phycoerythrin-con-
jugated anti-phospholipase Cg2( P L C g2) monoclonal antibody (1:200) (pY759;
BD Biosciences) at 4°C for 30 min, washed, and analyzed by ﬂow cytometry.
Statistical analyses. All statistical analyses were performed using the Prism
software package (GraphPad Software, Inc.). Survival curves were compared
using the log-rank test. All other comparisons were performed byunpaired two-
tailed t test.
FIG. 1. Generation of inducible Ptpn22 KD mice. A: Schematic representation of the inducible construct used for transgenesis. Long terminal
repeats (LTRs) ﬂank a cassette containing a tetracycline-regulated H1 promoter (H1-tetO) driving shRNA expression and a ubiquitin (Ubq)
promoter driving expression of the TetR and GFP. Addition of doxycycline (dox) derepresses the H1 promoter and induces shRNA expression.
B:T h es i l e n c i n ge f ﬁciency of shRNAs P2 and P4 was validated by cotransfection into 293-F cells of a Ptpn22 luciferase reporter and lentiviral vectors
containing constitutively expressed P2 or P4 shRNA. C: 293-F cells were infected with inducible P2 or P4 lentivirus, cultured in the presence or
absence of dox, and transfected with the Ptpn22 luciferase reporter to test for inducibility of the KD constructs. Data in B and C are representative of
two independent experiments. D: Representative GFP expression in blood lymphocytes from transgenic P2 and P4 mice. Forward- and side-scatter
characteristics were used to gate on the lymphocytic population. Open histogram, nontransgenic; solid histogram, transgenic.
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Generation of inducible Ptpn22 KD NOD mice. To in-
vestigate the effect of PTPN22 gene variation within an
experimental model of autoimmunity, we generated NOD
mice in which Ptpn22 can be inducibly silenced. The NOD
strain is a widely used model for type 1 diabetes (19), and
the spontaneous onset of autoimmunity in this background
makes it particularly useful to study genetic factors that
contribute to disease risk. We used lentiviral transgenesis
to introduce into NOD zygotes a construct encoding an
shRNA against Ptpn22 under the control of a tetracycline-
regulatable promoter (FH1t-UTG) (17,18). This lentiviral
vector includes the coding sequences for the TetR and
green ﬂuorescent protein (GFP) (Fig. 1A). To control for
possible off-target effects of RNA interference and for in-
sertional effects of the transgene, we generated two
transgenic lines with distinct shRNA sequences. We ﬁrst
validated the KD efﬁciency of several shRNA constructs
against Ptpn22 using a luciferase reporter assay. After
identifying two shRNA sequences that potently silenced
the Ptpn22 reporter when expressed from a constitutively
active promoter (Fig. 1B), we cloned these sequences,
termed P2 and P4, into the inducible FH1t-UTG vector
(18). We repeated the luciferase reporter assay with cells
that had been transduced with the FH1t-P2-UTG or FH1t-
P4-UTG lentivirus. We detected potent gene silencing only
in cells grown in the presence of the inducing agent
doxycycline (Fig. 1C), conﬁrming the functionality of these
inducible constructs. We proceeded with the generation of
two transgenic lines using FH1t-P2-UTG and FH1t-P4-UTG
lentivirus and obtained founders for both lines (Fig. 1D).
These were bred for several generations to generate P2
and P4 mice carrying a single copy of the transgene (ver-
iﬁed by Southern blotting of genomic DNA [data not
shown]). Potent Ptpn22 KD was measured both at the
mRNA and the protein level in doxycycline-treated but not
in untreated transgenic mice (Fig. 2A and B). Of note, gene
silencing was consistently more effective in P2 than in P4
mice (Fig. 2C).
Ptpn22 silencing expands the peripheral Treg-cell
compartment. Transgenic mice were treated with doxy-
cycline for various periods to investigate the effect of
Ptpn22 silencing in adult animals. Although 10–14 days of
treatment were sufﬁcient to induce potent Ptpn22 KD (Fig.
2), we detected no change in the distribution or phenotype
of immune cell populations after this short duration of
treatment (data not shown). In contrast, prolonged treat-
ment (.1 month) caused a signiﬁcant increase in the
proportion of FoxP3
+ Treg cells in secondary lymphoid
organs (Fig. 3A). To investigate whether the expansion of
Treg cells in treated mice affected their function, we tested
their activity in vitro and found that Ptpn22 KD Treg cells
remained suppressive (Fig. 3B). These results are con-
sistent with observations made in Ptpn22 KO B6 mice,
where Treg cells are similarly increased and retain their
suppressive function (15). The Treg-cell increase in sec-
ondary lymphoid organs of P2 and P4 mice appeared to
be independent of thymic output because the proportion
of FoxP3
+CD4
+CD8
– thymocytes was not affected by gene
silencing (Fig. 3C), even when Ptpn22 inhibition was
initiated before birth (Fig. 3D). To further interrogate
the origin of expanded Treg cells in Ptpn22 KD mice,
we quantiﬁed the proportion of Helios-expressing
FoxP3
+CD4
+ T cells in doxycycline-treated and -untreated
mice (Fig. 3E). Helios was reported to be a marker for
thymus-derived Treg cells, also known as natural Treg
(nTreg) cells (20). Of note, subsequent data from several
groups indicated that Helios could be detected in induced
Treg (iTreg) cells in some instances (21–23), suggesting
that this molecule may not be a reliable marker to differ-
entiate nTreg from iTreg. Notwithstanding, because we
found no change in the proportion of Helios
+ Treg cells in
the periphery of Ptpn22 KD mice, we interpret our data as
signifying that no Treg subpopulation, whether Helios
expressing or not, is preferentially expanded after Ptpn22
silencing. We also tested whether the loss of Ptpn22 af-
fected the propensity of naïve T cells to convert into
FIG. 2. Validation of Ptpn22 silencing in transgenic P2 and P4 mice.
A: Quantitation of Ptpn22 mRNA levels in lymphocytes from untreated
P2 and P4 mice and from doxycycline (dox)-treated WT, P2, and P4
mice relative to Ptpn22 expression in untreated WT mice. DDCTs (DCT
of sample – DCT untreated WT such that an increase in DDCT indicates
lower mRNA levels) are shown. Data were averaged from four in-
dependent experiments. B: Quantitation of PEP (Ptpn22) protein by
Western blotting in lymphocytes from untreated or dox-treated (200
mg/mL) WT and P2 mice. TetR was also assayed to verify transgene
expression. C: Quantitation of PEP protein in lymphocytes after ex-
posure to increasing doses of dox (mg/mL) for both P2 and P4 mice.
Data in B and C are representative of six and two similar experiments,
respectively. All mice were 8–12 weeks old and had received dox for 10–
14 days. *P < 0.05. CT, cycle threshold.
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planation for the increase in Treg cells observed after gene
silencing. However, naïve CD4
+CD62L
hi T cells from WT
and Ptpn22 KD mice did not differ in their potential for
Treg conversion in vitro (Fig. 3F). Furthermore, we did not
detect any difference in the acute proliferative behavior of
Treg cells in vitro after Ptpn22 silencing (Fig. 3G and H).
The data suggest that the entire peripheral Treg-cell com-
partment is expanded by loss of Ptpn22 and that neither
thymic output of nTreg nor conversion of naïve T cells into
iTreg cells is responsible for this expansion in Ptpn22 KD
mice.
FIG. 3. Ptpn22 silencing increases peripheral but not thymic Treg-cell numbers. A: The percentage of FoxP3
+CD4
+ T cells in lymph nodes (LNs) or
spleen of untreated or doxycycline (dox)-treated (for 4 weeks from the age of 8 weeks) WT, P2, and P4 mice relative to untreated WT (LN 11.23%,
spleen 16.7%). Data were averaged from three mice per group and are representative of 13 similar experiments. B: Proliferation of WT CD4
+CD25
–
T cells in response to anti-CD3 stimulation was measured in the presence or absence of CD4
+CD25
+ T cells from WT or P2 mice treated with dox for
2 weeks from the age of 8 weeks. Data are mean 6 SEM of triplicates and are representative of three independent experiments. C: The percentage
FoxP3
+CD4
+CD8
– T cells in the thymus of untreated or dox-treated (as in A) WT, P2, and P4 mice relative to untreated WT (7.27%). D:T h e
percentage FoxP3
+CD4
+CD8
– T cells in the thymus of untreated or dox-treated (for 2 months from birth) WT, P2, and P4 mice. E: The percentage
of Helios-negative cells among FoxP3
+CD4
+ T cells in lymph nodes from untreated or dox-treated (as in A) WT, P2, and P4 mice. Data in C, D, and E
were averaged from three to four mice per group and are representative of ﬁve (C and E) and two (D) similar experiments. F: CD62L
hiCD4
+ T cells
from untreated or dox-treated (for 2 weeks from 8 weeks of age) WT and P2 mice were activated in the presence of transforming growth factor-b
(with or without dox) for 3 days before measuring FoxP3 expression. Data are representative of two independent experiments. G and H: Pro-
liferation at 72 h (G) and fold numerical expansion after 10 days in culture (H) of Treg cells from dox-treated (for 2 weeks from 6 weeks of age) or
untreated WT, P2, and P4 mice after stimulation with CD3- and CD28-antibody–coated beads; data are mean 6 SEM of triplicate measurements.
**P < 0.01. NS, not signiﬁcant at P > 0.05.
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hiCD62L
lo (Teff) cells
within the CD4
+ T-cell compartment were quantiﬁed in WT, P2, and P4 mice that had either been untreated, treated for 2 months from birth, or
treated for 3 months from the age of 6 weeks. Data for CD8
+ T cells were similar (not shown). Data are averaged (mean 6 SEM) for two to six mice
per group and are representative of two (doxycycline [dox] from birth) and six (dox from 6 weeks) similar experiments. B: Cellularity of spleens
from WT, P2, and P4 mice untreated or treated with dox for 4–5 months from the age of 10 weeks averaged (mean 6 SEM) for 14 WT, 5 P2, and 8 P4
mice (untreated groups) and 19 WT, 10 P2, and 9 P4 mice (treated groups). C: Relative distribution of B cells, CD4 and CD8 T cells, dendritic cells
(DC), and macrophages (Mp) in the spleen of WT and P2 mice either untreated or treated from the age of 4 weeks for a duration of 4 months. Data
are averaged (mean 6 SEM) from ﬁve mice per group and representative of four similar experiments. D: Quantiﬁcation of naïve (CD44
loCD62L
hi)
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silencing on Teff-cell differentiation. The loss of
Ptpn22 in gene-deﬁcient B6 mice was shown to cause
a signiﬁcant expansion of Teff cells in older mice (14). In
Ptpn22 KD mice, a similar increase in CD44
hiCD62L
lo T
cells was apparent when gene silencing was induced from
birth (Fig. 4A). In contrast, even though induction of
Ptpn22 silencing in adult mice for a duration of several
months caused signiﬁcant splenomegaly (Fig. 4B), expan-
sion of the Teff-cell compartment was almost undetectable
after delayed gene silencing (Fig. 4A). The overall distri-
bution of lymphocyte populations in the spleen of treated
mice was not signiﬁcantly altered, suggesting that ho-
meostasis of both T and B cells was increased by Ptpn22
inhibition (Fig. 4C), although this effect was markedly
weaker in the CD8
+ T-cell compartment. Using two dif-
ferent strategies, we tested the propensity of naïve T cells
to differentiate into Teff cells more directly. First, we
transferred a mixture of WT and transgenic CD4
+ T cells
into NOD.scid recipients and examined the fate of these
cells 1 month after transfer. In this setting, T cells from
Ptpn22 KD animals did not differ from WT cells in their
propensity to differentiate into Teff cells (Fig. 4D). In
contrast, when we injected WT or transgenic mice with
anti-CD3 antibody, we found that Ptpn22 silencing greatly
promoted the activation and differentiation of T cells after
this stimulus (Fig. 4E). The difference between these two
experiments may be accounted for by the fact that the ac-
quisition of an effector phenotype following lymphopenia-
induced expansion likely differs from that caused by
a strong T-cell receptor stimulus, such as anti-CD3. The
data thus conﬁrm that Ptpn22 modulates the propensity of
naïve cells to differentiate into Teff cells but suggest that
the increase of Teff cells observed in Ptpn22 KO mice
largely depends on altered thymic selection in early stages
of development when thymic output is most inﬂuential on
the peripheral T-cell repertoire. Our inducible system
demonstrates that Ptpn22 inhibition in adult animals has
a lesser impact on the differentiation of naïve T cells into
Teff cells, at least under homeostatic conditions. This
contrasts with effects on Treg cells that were detectable
irrespective of the timing of Ptpn22 silencing.
B-cell activation and apoptosis are increased by
Ptpn22 silencing. Characterization of Ptpn22 KO mice
had revealed an increase in serum antibody titers (14),
albeit no increase in autoantibodies and no detailed anal-
ysis of B-cell function have been reported from these mice
to date. In humans, B cells from carriers of the PTPN22
susceptibility allele display decreased activation (3,10,11)
and resistance to apoptosis (11). In addition, LYP R620W
was found to reduce Syk, Akt, and PLCg2 phosphorylation
after B-cell receptor ligation (11), which would be con-
sistent with a gain of function of this variant. In light of
these observations, we sought to directly correlate loss of
PEP activity with B-cell function using Ptpn22 KD mice.
Ptpn22 silencing increased the upregulation of both CD25
and CD69 in B cells after anti-IgM stimulation (Fig. 5A).
Furthermore, a higher fraction of B cells became
CD25
+CD69
+ in response to both anti-IgM and anti-CD40
when Ptpn22 expression was inhibited (Fig. 5B). At the
same time, Ptpn22 KD B cells displayed decreased sur-
vival in culture compared with WT cells (Fig. 5C). Al-
though cells from P2 and P4 mice were concordant in most
respects, the difference in KD efﬁciency between these
two transgenic lines became most apparent when B-cell
proliferation was quantiﬁed after in vitro stimulation (Fig.
5D). B cells from P2 mice proliferated more vigorously
than cells from both WT and P4 animals in response to
both anti-IgM and anti-CD40. Similarly, B cells from P2
mice displayed increased phosphorylation of PLCg2, but
Ptpn22 silencing in P4 cells was insufﬁcient to effect
a detectable change in PLCg2 phosphorylation (Fig. 5E).
These combined results demonstrate that the inhibition of
Ptpn22 has the exact opposite effect on B-cell signaling
compared with the human R620W variant, which decrea-
ses activation and PLCg2 phosphorylation and increases
survival in response to stimulation (3,10,11).
Ptpn22 silencing protects P2 mice from autoimmune
diabetes. Based on evidence that disease-associated LYP
R620W is a gain-of-function variant, it was suggested that
LYP inhibition may protect against autoimmunity (8). Even
though the PTPN22 variation does not associate with
multiple sclerosis, PEP deﬁciency was recently found to
reduce the severity of EAE (15). The generation of an in-
ducible Ptpn22 KD model was aimed at evaluating the
therapeutic potential of Ptpn22 inhibition with a more
clinically relevant approach. The absence of PEP through-
out development in gene-deﬁcient mice causes changes in
thymic selection. The ensuing effects on the developing
immune system likely differ from alterations in cell function
caused by the acute inhibition of Ptpn22 in mature lym-
phocytes. We therefore opted to initiate Ptpn22 silencing
in adult animals to better mimic a therapeutic intervention
by LYP inhibition. To this end, we measured the frequency
of diabetes in transgenic mice and their WT littermates
that either had been left untreated or received doxycycline
from the age of 10 weeks. Doxycycline-treated P2 but not
P4 mice were signiﬁcantly protected from diabetes com-
pared with both untreated mice and treated WT mice (Fig.
6A and B). Disease frequency did not differ among un-
treated P2, P4, and WT mice. P4 mice showed no pro-
tection from disease, even when treated from an earlier
time point of 4 weeks of age (Fig. 6C). We speculate that
the weaker Ptpn22 KD in P4 mice may explain the dif-
ference in disease susceptibility between the two trans-
genic lines. This would be consistent with our observation
that P4 lymphocytes showed less marked differences from
the WT phenotype than P2 cells. Even though this differ-
ence in disease susceptibility may need to be resolved, it is
apparent that Ptpn22 inhibition did not increase the risk of
autoimmune diabetes in either transgenic line, contrary to
what would be predicted from a study claiming that
R620W is a loss-of-function variant (13). Instead, consis-
tent with results in the EAE model (15), Ptpn22 silencing
protected from autoimmune pathology.
DISCUSSION
After the discovery of the PTPN22 association with auto-
immune diabetes, several groups carried out functional
and effector (CD44
hiCD62L
lo) cells in mixed WT and P2 or WT and P4 CD4
+ T-cell populations before and after (32–35 days) transfer into NOD.
scid mice. WT and transgenic cells were identiﬁed on the basis of GFP expression. E: The percentage of CD44
hiCD62L
lo (Teff) cells was quantiﬁed
in CD4
+ and CD8
+ T cells from WT and P2 mice (pretreated with dox for 10 days) 2 days after injection with PBS only or anti-CD3 antibody 10 mg.
Data in D and E are averaged from three to four mice per group and representative of two independent experiments each. *P < 0.05; **P < 0.01.
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susceptibility variant and found evidence that the disease
allele is a gain-of-function variant (3,8–11). Data from an-
imal models did not unequivocally support these ﬁndings
because Ptpn22 KO mice appear to present signs of lym-
phocyte activity predisposing to autoimmunity (14). Fur-
thermore, combining Ptpn22 deﬁciency with a mutant
allele of CD45 caused lupus-like autoimmunity in double-
mutant mice, and this evidence was interpreted as the
disease allele being a loss-of-function variant (24). Finally,
a notable study published in 2011 suggested that the
PTPN22 disease variant encodes an LYP protein that is
more prone to degradation than the protective variant.
Knockin of a mutant Ptpn22 allele that encodes PEP
619W, the homolog of human LYP R620W, caused a phe-
notype reminiscent of Ptpn22 KO (13). However, despite
an accumulation of Teff cells and increased serum anti-
body levels, Ptpn22 KO mice do not develop any signs of
overt autoimmunity (14) possibly because of an increase in
Treg-cell numbers (15). The present data from Ptpn22 KD
NOD mice conﬁrm that the peripheral Treg-cell compart-
ment is increased in the absence of PEP. In contrast to
Ptpn22 KO B6 mice, however, transgenic NOD mice did
not have a higher proportion of FoxP3
+ thymocytes. We
observed in NOD mice that the expansion of Treg cells
caused by the loss of PEP can occur independently of
thymic output, indicating that Ptpn22 plays a role in the
peripheral homeostasis of Treg cells. Of note, Treg-cell
numbers in Ptpn22 KO mice were more substantially in-
creased than in our KD model, and this may be due to both
the incomplete loss of PEP in Ptpn22 KD mice and the
additive effect in KO mice of greater thymic output to-
gether with direct effects on peripheral Treg cells. In this
regard, however, it has been reported that a signiﬁcant
proportion of FoxP3
+ cells found in the thymus is not re-
cently generated but may in fact represent either long-term
resident cells or cells that have recirculated into the thy-
mus from the periphery (25,26). In light of the recent ob-
servation that the homeostasis of thymic resident Treg
cells depends on signals distinct from those governing
Treg-cell development (26), this raises the possibility that
the increased Treg-cell population observed in the thymus
of Ptpn22 KO mice (15) may in fact be a consequence of
the expansion of the mature Treg-cell compartment.
How Ptpn22 silencing exerts its effect on peripheral
Treg cells is not entirely clear, but we suggest that con-
version of naïve T cells into iTreg cells is not involved.
First, we did not observe increased efﬁciency of Treg
conversion in vitro after Ptpn22 silencing, and second, the
proportion of Helios-negative FoxP3
+ cells [presumed
nonthymic Treg cells (20), although some iTreg cells may
also express Helios (21–23)] was not altered after Treg-cell
expansion. Loss of PEP did not change the acute pro-
liferative behavior of Treg cells but may instead increase
homeostatic T-cell receptor signals essential for their pe-
ripheral maintenance and could decrease their re-
quirement for IL-2 (27), allowing expansion of the Treg-cell
niche. Alternatively, IL-2 levels may increase as a conse-
quence of facilitated differentiation and activation of Teff
cells and/or other immune cells producing IL-2, and loss of FIG. 5. Ptpn22 silencing increases activation and decreases survival
of transgenic B cells. B cells from WT, P2, and P4 mice treated
with doxycycline for 4 weeks from 8 weeks of age were stimulated
with anti-IgM (A–E) or anti-CD40 (B–D) at the indicated concen-
tration. Mean ﬂuorescence intensity (MFI) of CD25 and CD69
staining (A), percentage of CD25
+CD69
+ cells (B), and percentage of 7-
aminoactinomycin D negative (7-AAD
–) (nonapoptotic) cells (C) were
quantiﬁed 24 h after stimulation. Proliferation was measured by
3H-
thymidine incorporation 48 h poststimulation (D). The phosphorylation
of PLCg2 was measured at a single concentration of anti-IgM (40
mg/mL) at the indicated time poststimulation (E). Data are representative
of four (A–C), seven (D), and two (E) independent experiments. Data
are mean 6 SEM of triplicate measurements. *P < 0.05; **P < 0.01.
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a cell-extrinsic manner.
Although neither the present study nor the previous
report demonstrating expansion of Treg cells in Ptpn22-
deﬁcient animals showed a direct link between this ex-
pansion and protection from autoimmunity, it is tempting
to speculate a causal effect. Both protection from EAE in
Ptpn22 KO mice and protection from autoimmune di-
abetes in P2 NOD mice shown here may be imparted by
a more potent Treg-cell compartment.
Unlike its effect on Treg cells, Ptpn22 KD modulation of
Teff-cell differentiation seemed to take effect primarily at
the level of thymic development. Treatment of Ptpn22 KD
mice from birth had a vastly more signiﬁcant outcome than
gene silencing initiated in adult mice. This may be
explained by changes in positive selection described pre-
viously (14). Alterations of thymic selection can be pre-
dicted to have a lesser impact on the peripheral T-cell
repertoire once thymic output starts waning (i.e., in adult
animals).
Further, our work demonstrates that loss of Ptpn22
causes hyperreactivity and decreases survival of B cells.
Because B cells are essential for the full penetrance of
autoimmune diabetes in NOD mice (28), a defect in B-cell
function may synergize with increased Treg-cell numbers
in reducing the risk of autoimmune diabetes. In this con-
text, it is of interest that the lack of protection observed in
P4 mice correlates with a lesser dysfunction of B cells in
vitro, and further work will be required to determine the
relative contributions of the Treg- and B-cell compart-
ments to the protected disease phenotype of P2 mice.
Data reported for B cells from individuals carrying the
PTPN22 susceptibility allele are contradictory (10–13). The
phenotype of Ptpn22 KD B cells presented here is the exact
opposite of observations made for R620W by groups sug-
gesting a gain of function (10,11) yet matches data obtained
for this variant by the group proposing a loss of function
(13). Consequently, we cannot draw an unequivocal con-
clusion about what functional change the human disease
variant may cause based solely on cellular phenotypes.
However, because we did not observe disease exacerba-
tion after Ptpn22 inhibition, the ﬁndings are difﬁcult to
reconcile with the hypothesis that the PTPN22 disease al-
lele is a loss-of-function variant caused by accelerated
degradation of LYP (13). Instead, the results are most
consistent with LYP R620W being a gain-of-function vari-
ant. In conclusion, we suggest that the present study of
Ptpn22 inhibition in the NOD mouse model supports ear-
lier claims that the susceptibility allele of PTPN22 is a gain-
of-function variant and that inhibition of LYP may have
therapeutic value for the treatment of autoimmunity.
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